Contributions
Abstract: 54
Type: Scientific Session
Abstract Category: N/A
The number of available therapeutic options for multiple sclerosis is unprecedented. Not only do neurologists can now access multiple highly potent immunotherapies for relapsing MS, but for the first time, proven therapies for progressive disease forms - including primary progressive MS - have become available. This talk will summarise the current knowledge about the effectiveness of therapies for relapsing-remitting MS, and will explore the concept of episodic inflammatory activity as a marker and treatment target in progressive MS.
Disclosure: Tomas Kalincik served on scientific advisory boards for Roche, Genzyme-Sanofi, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Genzyme-Sanofi, Teva, BioCSL and Merck and received research support from Biogen.
Abstract: 54
Type: Scientific Session
Abstract Category: N/A
The number of available therapeutic options for multiple sclerosis is unprecedented. Not only do neurologists can now access multiple highly potent immunotherapies for relapsing MS, but for the first time, proven therapies for progressive disease forms - including primary progressive MS - have become available. This talk will summarise the current knowledge about the effectiveness of therapies for relapsing-remitting MS, and will explore the concept of episodic inflammatory activity as a marker and treatment target in progressive MS.
Disclosure: Tomas Kalincik served on scientific advisory boards for Roche, Genzyme-Sanofi, Novartis, Merck and Biogen, steering committee for Brain Atrophy Initiative by Genzyme, received conference travel support and/or speaker honoraria from WebMD Global, Novartis, Biogen, Genzyme-Sanofi, Teva, BioCSL and Merck and received research support from Biogen.